Functional studies of new gla gene mutations leading to conformational fabry disease

Archive ouverte

Filoni, C. | Caciotti, A. | Carraresi, L. | Cavicchi, C., Cc | Parini, R. | Antuzzi, D. | Zampetti, A. | Feriozzi, S. | Poisetti, P. | Garman, S.C. | Guerrini, R. | Zammarchi, E. | Donati, M.A. | Morrone, A.

Edité par CCSD ; Elsevier -

International audience. Fabry Disease (FD) is an X-linked multisystemic lysosomal disorder caused by mutations of α-galactosidase ( gene. Only a few of the 450 genetic lesions identified so far have been characterised by in vitro expression studies. Thus the significance of newly identified nucleotide variants in FD patients which lead to α-galactosidase (GAL-A) amino acid substitutions or intronic changes can be uncertain.

Suggestions

Du même auteur

Mechanisms of partner recognition by intrinsically disordered proteins

Archive ouverte | Dosnon, M. | CCSD

10th European-Biophysical-Societies-Association (EBSA) European Biophysics Congress, Dresden, GERMANY, JUL 18-22, 2015. International audience. no abstract

Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia

Archive ouverte | Di Filippo, M. | CCSD

International audience. BACKGROUND & AIMS: Non-alcoholic steatohepatitis leading to fibrosis occurs in patients with abetalipoproteinemia (ABL) and homozygous or compound heterozygous familial hypobetalipoproteinemi...

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus

Archive ouverte | Moreno-Martinez, D. | CCSD

International audience. Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are curr...

Chargement des enrichissements...